Search for: "Doe v. Abbott Laboratories" Results 21 - 40 of 205
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
17 May 2012, 9:26 pm by FDABlog HPM
Butler – Abbott Laboratories (“Abbott”) recently submitted a citizen petition to FDA regarding biosimilars under the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”). [read post]
30 Sep 2014, 4:03 pm by Michael Walsh
Abbott Laboratories does not apply to breach of warranty or fraud claims and a defendant is only liable for an apportionment equal to its then market share of the subject product. [read post]
19 Oct 2011, 11:27 am by Dennis Crouch
In 2005, the Court granted certiorari on related issues in Laboratory Corp. of America v. [read post]
24 May 2017, 8:36 am by Steven Cohen
 ABBOTT LABORATORIES – United States District Court – Eastern District of new York – May 22nd, 2017) involves the drug Depakote. [read post]
24 May 2017, 8:36 am by Steven Cohen
 ABBOTT LABORATORIES – United States District Court – Eastern District of new York – May 22nd, 2017) involves the drug Depakote. [read post]
1 Feb 2012, 11:15 am by Sean Wajert
Abbott Laboratories, et al., No. 2:10-cv-03242 (E.D. [read post]
11 Sep 2023, 4:00 am by Administrator
Canadian Securities Law Canadian Class Actions MonitorSaskatchewan Court of Appeal: Serial Certification Attempts Abusive In Abbott Laboratories, Ltd. v Spicer, the Saskatchewan Court of Appeal permanently stayed a proposed class action that was the last of five proposed national class actions concerning the drug sibutramine. [read post]